Cargando…
Sugammadex and anaphylaxis: An analysis of 33 published cases
In this study, the published sugammadex-induced anaphylaxis reports were reviewed to determine similarities in their presentation during anesthesia. PubMed was searched for sugammadex-induced anaphylaxis without time limitation. Reports were evaluated if they were in English and met the criteria of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289668/ https://www.ncbi.nlm.nih.gov/pubmed/34349361 http://dx.doi.org/10.4103/joacp.JOACP_383_19 |
_version_ | 1783724338747277312 |
---|---|
author | Arslan, Baris Sahin, Tuna Ozdogan, Hatice |
author_facet | Arslan, Baris Sahin, Tuna Ozdogan, Hatice |
author_sort | Arslan, Baris |
collection | PubMed |
description | In this study, the published sugammadex-induced anaphylaxis reports were reviewed to determine similarities in their presentation during anesthesia. PubMed was searched for sugammadex-induced anaphylaxis without time limitation. Reports were evaluated if they were in English and met the criteria of anaphylaxis determined by the World Allergy Organization. Two independent reviewers extracted and assessed the data using predesigned data collection forms. In total, 23 suitable articles were found and 33 sugammadex-induced anaphylaxis cases were included in the study. The mean age was 43.09 years (from 3–89 years) and 17 (51.5%) of the patients were female. Considering all reported cases, the average onset time of anaphylaxis was 3.08 min, with a median of 3 min (range 1–8 min). The most common signs and symptoms were hypotension, tachycardia, erythema, and desaturation. Of the 20 patients who underwent confirmatory skin testing, 15 had a positive skin reaction for sugammadex. Epinephrine was not given when indicated in about 25% of cases. Sugammadex-induced anaphylaxis onset time was less than 5 min in 92.3% of all the reported cases. Rapid diagnosis and early recognition of signs and symptoms of anaphylaxis are essential for a favorable prognosis. Treatment needs to be started as soon as possible to ensure the best outcome for the patient. |
format | Online Article Text |
id | pubmed-8289668 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-82896682021-08-03 Sugammadex and anaphylaxis: An analysis of 33 published cases Arslan, Baris Sahin, Tuna Ozdogan, Hatice J Anaesthesiol Clin Pharmacol Review Article In this study, the published sugammadex-induced anaphylaxis reports were reviewed to determine similarities in their presentation during anesthesia. PubMed was searched for sugammadex-induced anaphylaxis without time limitation. Reports were evaluated if they were in English and met the criteria of anaphylaxis determined by the World Allergy Organization. Two independent reviewers extracted and assessed the data using predesigned data collection forms. In total, 23 suitable articles were found and 33 sugammadex-induced anaphylaxis cases were included in the study. The mean age was 43.09 years (from 3–89 years) and 17 (51.5%) of the patients were female. Considering all reported cases, the average onset time of anaphylaxis was 3.08 min, with a median of 3 min (range 1–8 min). The most common signs and symptoms were hypotension, tachycardia, erythema, and desaturation. Of the 20 patients who underwent confirmatory skin testing, 15 had a positive skin reaction for sugammadex. Epinephrine was not given when indicated in about 25% of cases. Sugammadex-induced anaphylaxis onset time was less than 5 min in 92.3% of all the reported cases. Rapid diagnosis and early recognition of signs and symptoms of anaphylaxis are essential for a favorable prognosis. Treatment needs to be started as soon as possible to ensure the best outcome for the patient. Wolters Kluwer - Medknow 2021 2021-07-15 /pmc/articles/PMC8289668/ /pubmed/34349361 http://dx.doi.org/10.4103/joacp.JOACP_383_19 Text en Copyright: © 2021 Journal of Anaesthesiology Clinical Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Arslan, Baris Sahin, Tuna Ozdogan, Hatice Sugammadex and anaphylaxis: An analysis of 33 published cases |
title | Sugammadex and anaphylaxis: An analysis of 33 published cases |
title_full | Sugammadex and anaphylaxis: An analysis of 33 published cases |
title_fullStr | Sugammadex and anaphylaxis: An analysis of 33 published cases |
title_full_unstemmed | Sugammadex and anaphylaxis: An analysis of 33 published cases |
title_short | Sugammadex and anaphylaxis: An analysis of 33 published cases |
title_sort | sugammadex and anaphylaxis: an analysis of 33 published cases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289668/ https://www.ncbi.nlm.nih.gov/pubmed/34349361 http://dx.doi.org/10.4103/joacp.JOACP_383_19 |
work_keys_str_mv | AT arslanbaris sugammadexandanaphylaxisananalysisof33publishedcases AT sahintuna sugammadexandanaphylaxisananalysisof33publishedcases AT ozdoganhatice sugammadexandanaphylaxisananalysisof33publishedcases |